Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Aug 31;8(8):CD010967.
doi: 10.1002/14651858.CD010967.pub2.

Topical clonidine for neuropathic pain

Anna Wrzosek  1 , Jaroslaw Woron, Jan Dobrogowski, Joanna Jakowicka-Wordliczek, Jerzy Wordliczek
Affiliations
Meta-Analysis

Topical clonidine for neuropathic pain

Anna Wrzosek et al. Cochrane Database Syst Rev. .

Update in

  • Topical clonidine for neuropathic pain in adults.
    Serednicki WT, Wrzosek A, Woron J, Garlicki J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J, Zajaczkowska R. Serednicki WT, et al. Cochrane Database Syst Rev. 2022 May 19;5(5):CD010967. doi: 10.1002/14651858.CD010967.pub3. Cochrane Database Syst Rev. 2022. PMID: 35587172 Free PMC article.

Abstract

Background: Clonidine is a presynaptic alpha-2-adrenergic receptor agonist used for many years to treat hypertension and other conditions, including chronic pain. Adverse events associated with systemic use of the drug have limited its application. Topical use of drugs is currently gaining interest, as it may limit adverse events without loss of analgesic efficacy. Topical clonidine (TC) formulations have been investigated recently in clinical trials.

Objectives: The objectives of this review were to assess the analgesic efficacy of TC for chronic neuropathic pain in adults and to assess the frequency of adverse events associated with clinical use of TC for chronic neuropathic pain.

Search methods: We searched the Cochrane Register of Studies (CRS) Online (Cochrane Central Register of Controlled Trials (CENTRAL)), MEDLINE and EMBASE databases, reference lists of retrieved papers and trial registries, and we contacted experts in the field. We performed the most recent search on 17 September 2014.

Selection criteria: We included randomised, double-blind studies of at least two weeks' duration comparing TC versus placebo or other active treatment in patients with chronic neuropathic pain.

Data collection and analysis: Two review authors extracted data from the studies and assessed bias. We planned three tiers of evidence analysis. The first tier was designed to analyse data meeting current best standards, by which studies reported the outcome of at least 50% pain intensity reduction over baseline (or its equivalent) without use of the last observation carried forward or other imputation method for dropouts, reported an intention-to-treat (ITT) analysis, lasted eight weeks or longer, had a parallel-group design and included at least 200 participants (preferably at least 400) in the comparison. The second tier was designed to use data from at least 200 participants but in cases in which one of the above conditions was not met. The third tier of evidence was assumed in other situations.

Main results: We included two studies in the review, with a total of 344 participants. Studies lasted 8 weeks and 12 weeks and compared TC versus placebo. 0.1%. TC was applied in gel form to the painful area two to three times daily.Studies included in this review were subject to potential bias and were classified as of moderate or low quality. One drug manufacturer supported both studies.We found no top-tier evidence for TC in neuropathic pain. Second-tier evidence indicated slight improvement after the drug was used in study participants with painful diabetic neuropathy (PDN). A greater number of participants in the TC group had at least 30% reduction in pain compared with placebo (risk ratio (RR) 1.35, 95% confidence interval (CI) 1.03 to 1.77; number needed to treat for an additional beneficial outcome (NNTB) 8.33, 95% CI 4.3 to 50). Third-tier evidence indicated that TC was no better than placebo for achieving at least 50% reduction in pain intensity and on the Patient Global Impression of Change Scale. The two included studies could be subject to significant bias. We found no studies that reported other neuropathic pain conditions.The rate of adverse events did not differ between groups, with the exception of a higher incidence of mild skin reactions in the placebo group, which should have no clinical significance.

Authors' conclusions: Limited evidence from a small number of studies of moderate to low quality suggests that TC may provide some benefit in peripheral diabetic neuropathy. The drug may be useful in situations for which no better treatment options are available because of lack of efficacy, contraindications or adverse events. Additional trials are needed to assess TC in other neuropathic pain conditions and to determine how patients who have a chance to respond to the drug should be selected for treatment.

PubMed Disclaimer

Conflict of interest statement

Anna Wrzosek has no relevant conflicts of interest to declare.

Jaroslaw Woron has no relevant conflicts of interest to declare.

Jan Dobrogowski has no relevant conflicts of interest to declare.

Joanna Jakowicka‐Wordliczek has no relevant conflicts of interest to declare.

Jerzy Wordliczek has no relevant conflicts of interest to declare.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Topical clonidine vs placebo in PDN, outcome: 1.1 Pain relief ≥ 30%.
5
5
Forest plot of comparison: 1 Topical clonidine vs placebo in PDN, outcome: 1.2 Participants with ≥ 1 adverse event.
1.1
1.1. Analysis
Comparison 1 Topical clonidine vs placebo in PDN, Outcome 1 Pain relief ≥ 30%.
1.2
1.2. Analysis
Comparison 1 Topical clonidine vs placebo in PDN, Outcome 2 Participants with ≥ 1 adverse event.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Campbell 2009 {published and unpublished data}
    1. Campbell C, Campbell J, Schmidt W, Brady K, Stouch B. Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo‐controlled clinical trial. The Journal of Pain 2009;4:S55.
Campbell 2012 {published data only}
    1. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012;153(9):1815‐23. - PMC - PubMed

References to studies excluded from this review

Byas‐Smith 1995 {published data only}
    1. Byas‐Smith MG, Max MB, Muir J, Kingman ACN, CN‐00115607. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two‐stage 'enriched enrollment' design. Pain 1995;60(3):267‐74. - PubMed
Davis 1991 {published data only}
    1. Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JN. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991;47(3):309‐17. - PubMed
Lauretti 2009 {published data only}
    1. Lauretti GR, Mattos AL, Lima ICPR, Matsumoto M, Resende CS. The clinical and laboratorial evaluation of transdermal ketamine, fentanyl, clonidine or their combination in chronic low back pain. European Journal of Pain 2009;13:S126.
Meno 2001 {published data only}
    1. Meno A, Arita H, Hanaoka K. [Preliminary report: the efficacy of clonidine hydrochloride ointment for postherpetic neuralgia]. Masui ‐ Japanese Journal of Anesthesiology 2001;50(2):160‐3. - PubMed
Zeigler 1992 {published data only}
    1. Zeigler D, Lynch SA, Muir J, Benjamin J, Max MBCN, CN‐00084468. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48(3):403‐8. - PubMed

References to ongoing studies

NCT00661063 {published data only}
    1. Gozzani JL. Diabetic Neuropathy Topical Treatment. www.clinicaltrials.gov 2008.
NCT02068027 {published data only}
    1. Shaibani A. Safety and efficacy study of clonidine hydrochloride topical gel, 0.1% in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov 2014.

Additional references

Aley 1997
    1. Aley KO, Levine JD. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. Journal of Neuroscience 1997;17(2):735–44. - PMC - PubMed
Andrew 2014
    1. Andrew R, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. - PubMed
Anitescu 2013
    1. Anitescu M, Benzon HT, Argoff CE. Advances in topical analgesics. Current Opinion in Anaesthesiology 2013 Aug 29 [Epub ahead of print]. - PubMed
Apkarian 2011
    1. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49‐64. - PMC - PubMed
Asano 2000
    1. Asano T, Dohi S, Ohta S, Shimonaka H, Lida H. Antinociception by epidural and systemic alpha(2)‐adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesthesia & Analgesia 2000;90(2):400–7. - PubMed
Bernard 1994
    1. Bernard JM, Kick O, Bonnet F. Which way for the administration of alpha2‐adrenergic agents to obtain the best analgesia?. Cahiers d Anesthésiologie 1994;42(2):223–8. - PubMed
Bouhassira 2008
    1. Bouhassira D, Lanteri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380–7. - PubMed
Buerkle 1998
    1. Buerkle H, Yaksh TL. Pharmacological evidence for different alpha2‐adrenergic receptor sites mediating analgesia and sedation in the rat. British Journal of Anaesthesia 1998;81(2):208–15. - PubMed
Buerkle 2000
    1. Buerkle H. Peripheral antinociceptive action of alpha2‐adrenoceptoragonist. Baillière's Clinical Anaesthesiology 2000;2:411–8.
Chi 2007
    1. Chi L, Sekiyama H, Hayashida M, Takeda K, Sumida T, Sawamura S, et al. Effects of topical application of clonidine cream on pain behaviors and spinal Fos protein expression in rat models of neuropathic pain, postoperative pain, and inflammatory pain. Anesthesiology 2007;107(3):486‐94. - PubMed
Cochrane PaPaS Group 2011
    1. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. http://papas.cochrane.org/sites/papas.cochrane.org/files/uploads/L%20‐%2... (accessed 11 December 2013).
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Dias 1999
    1. Dias VC, Tendler B, Oparil S, Reilly PA, Snar P, White WB. Clinical experience with transdermal clonidine in African‐American and Hispanic‐American patients with hypertension: evaluation from a 12‐week prospective, open‐label clinical trial in community‐based clinics. American Journal of Therapeutics 1999;6(1):19–24. - PubMed
Dogrul 2004
    1. Dogrul A, Uzbay IT. Topical clonidine antinociception. Pain 2004;111(3):385‐91. - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. - PubMed
Eisenach 1995
    1. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D, Epidural Clonidine Study Group 2. Epidural clonidine analgesia for intractable cancer pain. Pain 1995;61(3):391–9. - PubMed
Eisenach 1996
    1. Eisenach JC, Kock M, Klimscha W. Alpha2‐adrenergic agonists for regional anesthesia: a clinical review of clonidine (1984–1995). Anesthesiology 1996;85:655–74. - PubMed
Finnerup 2015
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology 2015;14(2):162‐73. [PUBMED: 25575710.] - PMC - PubMed
Flores 2012
    1. Flores MP, Castro AP, Nascimento Jdos S. Topical analgesics. Revista Brasileira de Anestesiologia 2012;62(2):244‐52. - PubMed
Gentili 1996
    1. Gentili M, Juhel A, Bonnet F. Peripheral analgesic effect of intra‐articular clonidine. Pain 1996;64(3):593–6. - PubMed
Gentili 1997
    1. Gentili M, Houssel P, Osman M, Henel D, Juhel A, Bonnet F. Intra‐articularmorphine and clonidine produce comparable analgesia but the combination is not more effective. British Journal of Anaesthesia 1997;79(5):660–1. - PubMed
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. - PMC - PubMed
Hassenbusch 2002
    1. Hassenbusch SJ, Gunes S, Wachsman S, Willis KD. Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Medicine 2002;3:85–91. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.
Hurley 2013
    1. Hurley RW, Adams MC, Benzon HT. Neuropathic pain: treatment guidelines and updates. Current Opinion in Anaesthesiology 2013 Aug 29 [Epub ahead of print]. - PubMed
IASP Taxonomy Working Group 2011
    1. IASP Taxonomy Working Group. Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. Second Edition (Revised). http://www.iasp‐pain.org/AM/Template.cfm?Section=Classification_of_Chronic_Pain&Temp... (accessed 11 December 2014).
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204‐5. - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology 1991;10:276‐81. - PubMed
Kawaski 2003
    1. Kawasaki Y, Kumamoto E, Furue H, Yoshimura M. Alpha 2 adrenoceptor mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology 2003;98(3):682–9. - PubMed
Khaliq 2007
    1. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2] - DOI - PubMed
Khan 1999
    1. Khan ZP, Ferguson CN, Jones RM. Alpha‐2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999;54(2):146‐65. - PubMed
Kolesnikov 1999
    1. Kolesnikov YA, Pasternak GW. Topical opioid in mice: analgesia and reversal of tolerance by a topical N‐methyl‐D‐aspartate antagonist. Journal of Pharmacology and Experimental Therapeutics 1999;290:247–52. - PubMed
Kolesnikov 2000
    1. Kolesnikov YA, Chereshnev I, Pasternak GW. Analgesic synergy between topical lidocaine and topical opioids. Journal of Pharmacology and Experimental Therapeutics 2000;295:546‐51. - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. - PubMed
Lavand'homme 2002
    1. Lavand‘homme PM, Ma W, De KM, Eisenach JC. Perineural alpha(2A)‐adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology 2002;97:972–80. - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. - PMC - PubMed
Lunn 2009
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2] - DOI - PubMed
Lunn 2014
    1. Lunn Michael PT, Hughes Richard AC, Wiffen Philip J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 1. [DOI: 10.1002/14651858.CD007115.pub3; CD007115] - DOI - PMC - PubMed
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007.
Moisset 2007
    1. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80‐8. - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. McQuay HJ, Kalso E, Moore RA, editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ 978–0–931092–69–5]
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150:386‐9. - PubMed
Moore 2010b
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. - PMC - PubMed
Moore 2010c
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. - PubMed
Moore 2010d
    1. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers‐needed‐to‐treat analyses ‐ do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain 2010;151(3):592‐7. - PubMed
Moore 2011a
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] - DOI - PMC - PubMed
Moore 2011b
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. - PubMed
Moore 2011c
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. - PubMed
Moore 2013
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. - PubMed
Moore 2014
    1. Moore RA, Wiffen Philip J, Derry S, Toelle T, Rice Andrew SC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 4. [DOI: 10.1002/14651858.CD007938.pub3; CD007938] - DOI - PMC - PubMed
Neil 2011
    1. Neil MJ. Clonidine: clinical pharmacology and therapeutic use in pain management. Current Clinical Pharmacology 2011;6:280‐7. - PubMed
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. - PubMed
O'Connor 2009
    1. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122(10 Suppl):S22‐32. - PubMed
Ongioco 2000
    1. Ongioco RR, Richardson CD, Rudner XL, Stafford‐Smith M, Schwinn DA. Alpha2‐adrenergic receptors in human dorsal root ganglia: predominance of alpha2b and alpha2c subtype mRNSs. Anesthesiology 2000;92(4):968–76. - PubMed
Puskas 2003
    1. Puskas F, Camporesi EM, O'Leary CE, Hauser M, Nasrallah FV. Intrathecal clonidine and severe hypotension after cardiopulmonary bypass. Anesthesia & Analgesia 2003;97(5):1251–3. - PubMed
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56:127‐38. - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Riedl 2009
    1. Riedl MS, Schnell SA, Overland AC, Chabot‐Doré AJ, Taylor AM, Ribeiro‐da‐Silva A, et al. Coexpression of alpha 2A‐adrenergic and delta‐opioid receptors in substance P‐containing terminals in rat dorsal horn. Journal of Comparative Neurology 2009;513:385–98. - PMC - PubMed
Samso 1996
    1. Samso E, Valles J, Pol O, Gallart L, Puig MM. Comparative assessment of the anaesthetic and analgesic effects of intramuscular and epidural clonidine in humans. Canadian Journal of Anesthesia 1996;43(12):1195–202. - PubMed
Sawynok 2003
    1. Sawynok J. Topical and peripherally acting analgesics. Pharmacological Reviews 2003;55(1):1–20. - PubMed
Sierralta 1996
    1. Sierralta F, Naquira D, Pinardi G, Miranda HF. Alpha‐adrenoceptor and opioid receptor modulation of clonidine‐induced antinociception. British Journal of Pharmacology 1996;119(3):551–4. - PMC - PubMed
Smith 2013
    1. Smith BH, Lee J, Price C, Baranowski AP. Neuropathic pain: a pathway for care developed by the British Pain Society. British Journal of Anaesthesia 2013;111:73‐9. - PubMed
Soni 2013
    1. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community‐based study. Arthritis & Rheumatism 2013;65(7):1942‐9. - PMC - PubMed
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. - PMC - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281–9. - PubMed
Tracey 2011
    1. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173‐81. - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. - PMC - PubMed
Wiffen 2013
    1. Wiffen Philip J, Derry S, Moore RA, Aldington D, Cole P, Rice Andrew SC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013, issue 11. [DOI: 10.1002/14651858.CD010567.pub2; CD010567] - DOI - PMC - PubMed
Wiffen 2014
    1. Wiffen Philip J, Derry S, Moore RA, Kalso Eija A. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 4. [DOI: 10.1002/14651858.CD005451.pub3; CD005451] - DOI - PMC - PubMed
Woolf 1999
    1. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353(9168):1959‐64. - PubMed
Zhou 2013
    1. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013, issue 3. [DOI: 10.1002/14651858.CD007963.pub2; CD007963] - DOI - PubMed

MeSH terms